Other News To Note
Compugen Ltd., of Tel Aviv, Israel, said it demonstrated the therapeutic potential of CGEN-15022, a B7/CD28-like membrane protein, as an immune checkpoint target in multiple cancers. The company's results suggested CGEN-15022 is expressed in numerous types of epithelial cancers, including liver, colorectal, lung and ovarian cancers.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST